Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Neoplasms 19Endometrial Neoplasms 15Ovarian Neoplasms 11Carcinoma, Non-Small-Cell Lung 10Neoplasm Metastasis 7Squamous Cell Carcinoma of Head and Neck 6Uterine Cervical Neoplasms 5Head and Neck Neoplasms 5Breast Neoplasms 5Rectal Neoplasms 4Pancreatic Neoplasms 4Melanoma 4Lung Neoplasms 4Colonic Neoplasms 4Fallopian Tube Neoplasms 3Colorectal Neoplasms 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Recurrence 2Osteosarcoma 2Multiple Myeloma 2Locally Advanced Rectal Cancer (LARC) 2Carcinoma, Renal Cell 2Carcinoma, Neuroendocrine 2Carcinoma, Hepatocellular 2Carcinoma 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Turcot syndrome 1

Interventions

Cisplatin 55Carboplatin 49pembrolizumab 42Paclitaxel 42Gemcitabine 28Pemetrexed 23Radiotherapy 21Magnetic Resonance Spectroscopy 20Radiotherapy, Intensity-Modulated 18Cetuximab 18Docetaxel 17Specimen Handling 16Nivolumab 16Fluorouracil 16Cyclophosphamide 14durvalumab 13Bevacizumab 13Sorafenib 12Radiation 11Sunitinib 10Platinum 10130-nm albumin-bound paclitaxel 101,2-diaminocyclohexaneplatinum II citrate 10osimertinib 9Oxaliplatin 8Irinotecan 8Ipilimumab 8Everolimus 8Drug Therapy 8Capecitabine 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma × dostarlimab × Clear all
NCT05559879 2026-04-15

Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma

University of Alabama at Birmingham

Phase 1/2 Recruiting
37 enrolled
Gynecologic

Carcinoma, Uterine Neoplasms, Endometrial Neoplasms

NCT06317311 2025-07-25

RUBY-J

GlaxoSmithKline

Phase 2 Active not recruiting
41 enrolled
Gynecologic

Carcinoma, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡